Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 11:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,476 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Insulin-Dependent Diabetes Mellitus 1 Clear all

Conditions: Diabetes Mellitus, Type 1
Interventions: HDV-Insulin Lispro and Insulin Degludec (-40%), HDV-Insulin Lispro and Insulin Degludec (-10%); Drug
Lead sponsor: Diasome Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 7
States / cities: San Mateo, California • Aurora, Colorado • Atlanta, Georgia + 4 more

Conditions: Type I Diabetes
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 1 Diabetes
Interventions: ONBOARD; Behavioral
Lead sponsor: Molly Tanenbaum; Other
Eligibility: 18 Years to 50 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Type 1 Diabetes, Celiac Disease
Interventions: Gluten Challenge, Sham Challenge; Dietary Supplement
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes
Interventions: Garmin physical activity tracker; Other
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 8 Years to 21 Years
Enrollment: 45 participants
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Peripheral Neuropathy, Type 1 Diabetes
Interventions: Salsalate; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Type 1 Diabetes, Diabetes Distress
Interventions: StreamLine, TunedIn, FixIt; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 19 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes Mellitus, Type I
Interventions: Real-time glucose sensor; Device
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 3 Months to 3 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetic Ketoacidosis, Type 1 Diabetes Mellitus
Interventions: Glargine, Continuous Glucose Monitor (Abbott FreeStyle Libre Pro); Drug · Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 6 Years to 18 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Ketosis Prone Diabetes
Interventions: Continuous Glucose Monitoring, Insulin; Device · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Type 1 Diabetes Mellitus
Interventions: mAb hOKT3gamma1(Ala-Ala), Teplizumab, Placebo Arm; Drug
Lead sponsor: Yale University; Other
Eligibility: 8 Years to 30 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 4
States / cities: San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 1 more

Conditions: Type 1 Diabetes, Obesity
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: New York, New York

Conditions: Type I Diabetes
Interventions: Anakinra, Placebo Comparator; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 8 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes
Interventions: Atomoxetine, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Type 1
Interventions: Inhaled human insulin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 30
States / cities: Duarte, California • Long Beach, California • Los Angeles, California + 27 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Home Telehealth T1D C2oYoT1-HR, Personalized Behavioral Health, Personalized Adherence Feedback; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 10 Years to 17 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetes Mellitus, Type 1
Interventions: Dietary intervention; Behavioral
Lead sponsor: Physicians Committee for Responsible Medicine; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Diabetes Mellitus, Type 1
Interventions: No intervention; Other
Lead sponsor: Yale University; Other
Eligibility: 10 Years to 16 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Diabetes, Diabetes Mellitus, Type 1, Type1diabetes, Diabetes Mellitus
Interventions: YG1699, Dapagliflozin; Drug
Lead sponsor: Youngene Therapeutics Inc., Ltd.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Non Small Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Adenocarcinoma, Urothelial Carcinoma
Interventions: GRT-C901, GRT-R902, nivolumab, ipilimumab; Biological
Lead sponsor: Gritstone bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 10
States / cities: Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 6 more

Conditions: Type 1 Diabetes, Family Relations
Interventions: The 3Ms 2.0 Intervention, Educational Attention Control (EAC); Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 10 Years to 14 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Detroit, Michigan • Memphis, Tennessee

Conditions: Type 1 Diabetes
Interventions: Teplizumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: Not listed
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 24
States / cities: Little Rock, Arkansas • San Francisco, California • Aurora, Colorado + 19 more

Conditions: Type 1 Diabetes Mellitus
Interventions: CGM and Insulin Pump, Closed-Loop Control System; Device
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 21 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 3
States / cities: Santa Barbara, California • Rochester, Minnesota • Charlottesville, Virginia

Conditions: Diabetes Mellitus Type 1
Interventions: Insulin LISPRO, recombinant human insulin; Drug
Lead sponsor: Biodel; Industry
Eligibility: 19 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Chula Vista, California

Search by objective public record fields.

Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec

Assessment of Beta Cell Mass in Type 1 Diabetes With 11C-Dihydrotetrabenazine and PET Scan

Overcoming Barriers and Obstacles to Adopting Diabetes Devices (ONBOARD) Trial

Gluten Immunity and Islet Autoimmunity in Type-1 Diabetes

Garmin PACT (Physical Activity Tracking in Type 1 Diabetes Using Garmin Vivosmart)

Pilot Study to Determine Effects of Salsalate in Type 1 Diabetes and Painful Peripheral Neuropathy

Behavioral Approaches to Reducing Diabetes Distress and Improving Glycemic Control

The Effectiveness of Continuous Glucose Monitoring in Diabetes Treatment for Infants and Young Children

Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes

Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity

Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes

PET Scan Imaging of Beta Cell Mass

Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine

Six Month Clinical Trial Assessing Efficacy and Safety of Inhaled Insulin in Type 1 Diabetes

Home Telemedicine to Optimize Health Outcomes in High-Risk Youth With Type 1 Diabetes

Effect of a Dietary Intervention on Insulin Requirements in Type 1 Diabetes

Sleep, Coping and Executive Functioning in Youth With Type 1 Diabetes

A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes

A Study of a Personalized Neoantigen Cancer Vaccine

Family Intervention for Black Teens With Type 1 Diabetes

Description of Patients With Type 1 Diabetes Treated With Teplizumab

At Home Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAs) System and Run-to-Run Adaptation

Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes